Buy Imbruvica Near Me Online Cancer Treatment – Ibrutinib for Leukemia and Lymphoma Therapy

Name: Buy Imbruvica 140mg Online: Uses and Side Effects Explained
Price: 1200.00 USD
Availability: InStock

US FDA grants approval for Imbruvica for chronic lymphocytic

What is Imbruvica?

Imbruvica (ibrutinib) is used to treat Waldenström’s macroglobulinemia (WM), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and chronic graft versus host disease (cGVHD) in some people. Imbruvica is prescribed to slow cancer or disease progression in WM, CLL, SLL, and cGVHD. Imbruvica is given once day as a pill, tablet, or oral suspension.

Imbruvica works by inhibiting an enzyme known as Bruton’s tyrosine kinase (BTK), which reduces the survival of malignant B cells and delays the progression of CLL or SLL. Imbruvica aids in the movement of aberrant B cells out of the feeding surroundings of the lymph nodes, bone marrow, and other organs in WM, as well as the inhibition of particular immune cells involved in CGVHD.

Imbruvica is a prescription medication used to treat certain blood cancers, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström’s macroglobulinemia (WM). The active ingredient, ibrutinib, is a targeted therapy that works by blocking a specific protein (Bruton’s tyrosine kinase or BTK) that cancer cells need to grow and divide. Imbruvica helps slow the spread of cancer and is taken orally once daily, providing a convenient option for long-term cancer management.

How Imbruvica Works to Fight Cancer

Imbruvica works by inhibiting the BTK protein, which plays a key role in the survival and proliferation of B-cells, including cancerous B-cells. By blocking BTK, Imbruvica disrupts the signaling pathways that promote the growth of cancer cells, ultimately leading to their death. This mechanism makes Imbruvica effective against blood cancers such as CLL, MCL, and WM. It is often used as a first-line treatment or for patients who have not responded to other therapies, offering significant improvements in progression-free survival.

Use of Imbruvica ( What is Imbruvica used for)?

Imbruvica is FDA-approved for:

chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) in adults
chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion in adults
Waldenström’s macroglobulinemia (WM) in adults
chronic graft versus host disease (cGVH), after failure of one or more lines of systemic therapy for adult and pediatric patients aged 1 year and older.

How should I take Imbruvica?

Take Imbruvica exactly as directed by your doctor. Follow the recommendations on your prescription label and read any drug guidelines or instruction sheets.

Take this medication with a full glass of water, at the same time every day. Drink plenty of fluids when on Imbruvica.

Swallow the Imbruvica tablet or capsule whole and do not crush, chew, break, or open it.
Shake the oral suspension (liquid). Measure a dose with the supplied measuring device (not a kitchen spoon).

Inform your healthcare providers if you have a scheduled surgery. A lengthy illness may cause you to become dehydrated. If you are vomiting or have diarrhea, call your doctor.

You may become infected or bleed more easily. You will require regular blood and medical checks.

Imbruvica dosage

IMBRUVICA is an oral, once-a-day therapy that you can take with a glass of water, with or without food, on your own schedule. IMBRUVICA allows for easy oral dosing, allowing you to focus on what is most important.

The dose of Imbruvica varies depending on the condition being treated:

Imbruvica Dosage for Adults with CLL/SLL and WM

420mg once daily.

Imbruvica Dosage for cGVHD

Patients 12 years and older: 420mg once daily
Patients 1 year old to less than 12 years old: 240mg/m² once daily (up to a maximum dosage of 420mg once daily).

Dosing Modifications

Imbruvica side effects

Common side effects of Imbruvica

Common Imbruvica side effects include diarrhea, nausea, stomach ache, fever, cough, difficulty breathing, mouth sores, fatigue, low blood cell counts (including low platelets, red and white blood cell counts), muscle spasms, bruises, rash, and muscle, joint, or bone pain.

You may get infections more easily, even serious or fatal infections. Call your doctor right away if you have signs of infection such as:

fever, chills, sore throat
mouth sores, red or swollen gums;
pale skin, easy bruising, unusual bleeding; or
chest discomfort, wheezing, dry cough or hack, rapid weight loss.

Imbruvica may cause serious side effects. Call your doctor at once if you have:

severe or ongoing diarrhea;
heart problems – swelling, rapid weight gain, feeling short of breath;
heart rhythm disorders – dizziness, chest pain, shortness of breath, fast or irregular heart rate, feeling light-headed;
high blood pressure- severe headache, blurred vision, pounding in your neck or ears;
low blood cell counts – fever, chills, tiredness, mouth sores, skin sores, easy bruising, unusual bleeding, pale skin, cold hands and feet, feeling light-headed or short of breath.

Benefits of Imbruvica for Blood Cancer Treatment

Imbruvica provides several benefits for patients with blood cancers. Its targeted action focuses on the specific proteins that cancer cells rely on, leading to fewer side effects compared to traditional chemotherapy. It has shown remarkable efficacy in controlling cancer progression and improving overall survival rates. Additionally, Imbruvica is taken orally, allowing patients to manage their treatment at home without the need for hospital visits. It is also approved for use in multiple blood cancers, offering a versatile option for targeted therapy.

IMBRUVICA® Side Effects

FAQ

How long can you stay on Imbruvica (ibrutinib)?

Imbruvica (ibrutinib) is normally given forever if it is well tolerated, there is little disease progression, and no toxicity has occurred.

In rare cases, extremely good partial clinical responses can occur within three to six months.

However, most people are continued on Imbruvica indefinitely, regardless of clinical response. This is a common treatment strategy for people with certain types of leukemia and solid tumors because, when the treatment agent is stopped, symptoms can reappear and lymph nodes enlarge in a relatively short period of time, especially if patients haven’t been taking Imbruvica for long or have tried many other treatments.

Imbruvica therapy in clinical trials lasted an average of 41 months (range, 2-51 months). The average survival time after discontinuing Imbruvica was 8 months.

Is Imbruvica a chemotherapy drug?

Imbruvica (ibrutinib) is a targeted drug that inhibits the enzyme Bruton tyrosine kinase (BTK), a major signalling protein that is essential for the survival of certain malignancies, including B-cell leukemias and lymphomas.

Imbruvica suppresses BTK, which inhibits the impulses that cause malignant cells to proliferate and divide uncontrollably, resulting in cancer cell death.

Imbruvica is not a chemotherapy drug. It is a targeted treatment.
Imbruvica works by inhibiting the enzyme Bruton tyrosine kinase (BTK), which is part of a crucial signaling pathway in certain cancers, especially B-cell leukemias and lymphomas.
BTK plays an important role in the survival of cancer cells, telling them to grow and divide uncontrollably.
By blocking this pathway Imbruvica triggers the death of cancer cells.

Who makes Imbruvica?

Scientists at Celera Genomics developed the chemical that became known as Imbruvica to research the activity of the enzyme Bruton tyrosine kinase (BTK).

Pharmacyclics bought the molecule in 2006, along with a few other development initiatives, and renamed it PCI-32765.

Pharmacyclics and Johnson & Johnson agreed to co-develop the medicine in 2011, after the Phase II studies were finished, with J&J paying Pharmacyclics $150 million up front and $825 million in milestones.